PMC8408893_01
Plain X-ray: (a) pre-denosumab showed lytic lesion in left sacrum and (b) post-denosumab showed increased calcification in lesion.
10.1177_20363613211034710-fig1.jpg
PMC8408893_01_10.1177_20363613211034710-fig1.jpg
fig1-20363613211034710
Surveillance imaging throughout her treatment showed a decrease in the number and size of the cystic components, and an overall plain radiographic appearance of mineralization along with decreased FDG avidity on PET scan, suggestive of a treatment response (Figures 1 and 2).
(a) PET scan of pre-denosumab showed metabolically active lesion in sacrum and (b) post-denosumab showed no metabolic activity.
10.1177_20363613211034710-fig2.jpg
PMC8408893_01_10.1177_20363613211034710-fig2.jpg
fig2-20363613211034710
Surveillance imaging throughout her treatment showed a decrease in the number and size of the cystic components, and an overall plain radiographic appearance of mineralization along with decreased FDG avidity on PET scan, suggestive of a treatment response (Figures 1 and 2).
(a) The fluid levels seen here are very similar to those seen in ABCs and (b) loss of fluid levels in lesion.
10.1177_20363613211034710-fig3.jpg
PMC8408893_01_10.1177_20363613211034710-fig3.jpg
fig3-20363613211034710
After nearly 24 months of treatment with denosumab, her latest MRI has continued to show stable to slightly decreased size of the lesion and loss of fluid level in the lesion (Figure 3).